What the ‘Longevity Movement’ Is Finally Learning About Skin

A deep dive into palmitoylethanolamide, and what the science actually says.

There is a molecule your body produces right now, without any prompting, in response to stress, injury, and inflammation. It has been studied in over 600 clinical and preclinical trials. A Nobel Prize-winning scientist reportedly took it herself well into her hundreds. And until recently, it was almost entirely absent from mainstream longevity and skincare conversations.

Its name is palmitoylethanolamide, or PEA for short.

This is not a new discovery or a trend. PEA has been researched since the 1950s, appearing in studies spanning pain management, neurological health, immune function, and now, compellingly, skin health over time. What is new is the growing understanding of why it matters so much, and the connection it draws between systemic inflammation and what we see happening at the surface of the skin.

First: What Is PEA?

PEA is an endogenous fatty acid amide, meaning your body synthesises it naturally, producing it on demand when cells are under stress. Structurally, it is derived from palmitic acid (one of the most common fatty acids in the body) and belongs to a family of signalling molecules called N-acylethanolamines.¹

Unlike pharmaceutical anti-inflammatories, PEA does not suppress inflammation from the outside. It works by amplifying and regulating the body's own existing protective mechanisms and acting as what researchers call an "autacoid local injury antagonist," or ALIA. It is produced where it is needed, acts locally, and does not accumulate in tissues in the way synthetic compounds can.

Its primary mechanism is the activation of PPAR-α (peroxisome proliferator-activated receptor-alpha), a nuclear receptor that regulates the expression of inflammatory genes and plays a central role in controlling immune cell behaviour, particularly mast cells.²

The Context: Inflammaging

To understand why PEA is attracting serious attention in longevity medicine, it helps to understand inflammaging.

The term was coined in 2000 by gerontologist Claudio Franceschi to describe a phenomenon now considered one of the most significant factors in how the body changes over time: a state of chronic, low-grade, systemic inflammation that persists without an acute trigger, produces no obvious symptoms, and contributes to slow, cumulative changes across tissues and systems.³

Unlike acute inflammation, which is protective, localised, and resolves, inflammaging is a background hum that never fully settles. In the blood, pro-inflammatory cytokines including interleukin-6 (IL-6), interleukin-1β, and tumour necrosis factor-alpha (TNF-α) remain chronically elevated. These molecules are biologically active, influencing tissue remodelling, cellular repair, and the functional behaviour of organs and systems over decades.

Inflammaging has been linked to cardiovascular disease, neurodegeneration, metabolic dysfunction, and immune senescence. It also has a surface expression that is immediately visible and measurable, and deeply relevant to how skin changes over time.

What Inflammaging Means for Skin

Skin is not merely a cosmetic consideration. It is the body's largest organ, a primary interface with the external environment, and one of the most responsive indicators of systemic inflammatory status.

The mechanisms through which chronic low-grade inflammation influences how skin ages are now well documented:

Collagen remodelling. Pro-inflammatory cytokines upregulate matrix metalloproteinases (MMPs), enzymes that break down collagen and elastin. A 2025 review in the Journal of Cosmetic Dermatology notes that chronic low-grade inflammation contributes to structural tissue changes, disrupts barrier function, and reduces the skin's capacity for efficient self-repair.⁴ The result is not simply a slowdown in collagen production — it is an acceleration in how quickly existing collagen is broken down.

Barrier integrity. Chronic inflammation disrupts the tight junction proteins that maintain the skin barrier. When barrier integrity is affected, transepidermal water loss increases, skin becomes more reactive, and its resilience to environmental stressors is reduced.

Cellular repair and turnover. Inflammaging slows the resolution phase of the skin's repair cycle, meaning microinjuries and daily stressors accumulate rather than being cleared efficiently. This shows up as reduced luminosity and slower surface renewal over time.

Mast cell activity. Mast cells play a central role in skin immune function. Under inflammatory conditions, they become overactivated, releasing histamine, prostaglandins, and cytokines that sustain the inflammatory state and further affect barrier function.

How PEA Relates to These Mechanisms

PEA's relevance here lies in its capacity to modulate inflammation at the cellular level — specifically in the pathways most associated with how skin changes over time.

PPAR-α activation. When PEA binds to PPAR-α, it modulates the transcription of pro-inflammatory genes, reducing the production of cytokines ( IL-6, TNF-α, MCP-2) associated with inflammaging.² This is not a blunt suppressive effect; it is a regulatory one, supporting the return of overactive signalling toward homeostasis rather than dampening immune function broadly.

Mast cell modulation. Research has consistently shown that PEA down-modulates mast cell degranulation, reducing the release of histamine, PGD₂, and TNF-α from activated mast cells.⁵ In mouse models of contact allergic dermatitis, PEA reduced mast cell infiltration and attenuated angiogenic responses associated with chronic skin inflammation.⁶

Skin barrier support. In vitro studies using PEA incorporated into nano-liposomes found significant upregulation of filaggrin (FLG), a key structural protein critical to skin barrier integrity and hydration. The same research found downregulation of MMP-1 and MMP-3, enzymes involved in collagen breakdown, following PEA treatment.⁷

Clinical evidence in dermatology. A double-blind, comparator-controlled randomised clinical trial published in 2024 investigated the efficacy of topical Levagen®+, a bioavailable form of PEA, in participants with eczema symptoms. 72 participants with dry, red, scaling, and itchy skin were treated over four weeks. Redness reduced by week two; dryness by week four. Participants reported overall improvement in total eczema symptom severity, without the use of steroidal rescue medication.⁸ A separate 2024 systematic review of PEA RCTs noted significant improvements in symptom severity, dryness, and itch in patients with atopic dermatitis, with outcomes surpassing a standard moisturiser on several measures.⁹

The Bioavailability Question

One reason PEA remained underutilised for so long, despite its research profile, is a practical one: as a lipophilic (fat-soluble) molecule, standard PEA has limited bioavailability. In its unprocessed crystalline form, it does not disperse readily in water, which affects how efficiently it is absorbed.

Levagen®+ was developed to address this directly.

Using LipiSperse® technology, a cold-water dispersible delivery system developed by Pharmako Biotechnologies that reduces particle aggregation of lipophilic ingredients, Levagen®+ was tested in a parallel, double-blind pharmacokinetic study published in the Journal of Nutraceuticals and Food Science. Twenty-eight healthy participants were randomised to receive either 300 mg of Levagen®+ or 300 mg of standard, unprocessed PEA.

The results: Levagen®+ increased plasma PEA concentration by 1.75 times compared to standard PEA, with peak absorption observed at 45 minutes post-ingestion.¹⁰

Bioavailability is not a technical footnote, it determines how much of an ingredient is actually available to act. Higher absorption means the clinical evidence translates more directly into real-world outcomes.

What This Means in Practice

The case for PEA in longevity medicine is built on a coherent body of evidence connecting a well-characterised molecular target (PPAR-α), a well-understood contributor to how the body changes over time (chronic low-grade inflammation), and a measurable surface outcome (skin structure, barrier integrity, and resilience).

What distinguishes PEA within this conversation is that it works at the level of cellular signalling, supporting the upstream conditions that influence how skin behaves over time, rather than addressing surface changes in isolation. Topical interventions such as retinoids, peptides, antioxidants have their place. But the inflammatory environment in which skin cells operate determines how effectively any of those interventions can work.

Skin is where this becomes visible. The same low-grade inflammatory activity that influences collagen remodelling in the dermis is implicated in vascular health, neurological function, and metabolic resilience. PEA does not operate in one system in isolation. It works across all of them.

For those thinking carefully about long-term skin health, not as a cosmetic project, but as a dimension of how the body sustains itself over time, the science around PEA is worth understanding.

References

1. Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on new formulations. Br J Pharmacol. 2017;174(11):1349–1365.

2. Skaper SD, Facci L, Barbierato M, et al. N-Palmitoylethanolamine and neuroinflammation: a novel therapeutic strategy of resolution. Mol Neurobiol. 2015;52:1034–1042.

3. Franceschi C, Bonafè M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–254.

4. Long X, et al. Mechanisms and interventions of skin ageing: a review. J Cosmet Dermatol. 2025. [Epub ahead of print]

5. Re G, Barbero R, Miolo A, Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J. 2007;173(1):21–30.

6. Petrosino S, Cristino L, Karsak M, et al. Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy. 2010;65(6):698–711.

7. Wei W, et al. Palmitoylethanolamide-incorporated elastic nano-liposomes for enhanced transdermal delivery and anti-inflammation. Pharmaceutics. 2024;16(7):876.

8. Gencor / Palmara Health. Efficacy of topical palmitoylethanolamide (Levagen®+) for the management of eczema symptoms: a double-blind, comparator-controlled, randomized clinical trial. Published 2024.

9. Bortoletto R, et al. Palmitoylethanolamide supplementation for human health: a state-of-the-art systematic review of randomized controlled trials in patient populations. Brain Behav Immun Health. 2024;43:100927.

10. Briskey D, et al. Increased absorption of palmitoylethanolamide using a novel dispersion technology system (LipiSperse®). J Nutraceuticals Food Sci. 2020;5(1).

This article is for educational purposes and does not constitute medical advice. Genaura's formulation contains Levagen®+ as its active ingredient. The clinical trials referenced relate to the Levagen®+ ingredient. Individual results from the finished serum may vary.